CytomX Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-43.1M | $-58.9M | $-35.4M | $-30.3M | $-15.1M |
| Depreciation & Amortization | $1.6M | $1.7M | $1.2M | $783.0K | $655.0K |
| Depreciation | $1.5M | $1.7M | $1.2M | — | — |
| Amortization | $146.0K | — | — | — | — |
| Stock-Based Compensation | $11.3M | $10.1M | $4.0M | $553.0K | $343.0K |
| Net Cash from Operating Activities | $170.4M | $-2.0M | $-27.4M | $31.8M | $-8.0M |
| Investing Activities | |||||
| Capital Expenditures | $1.6M | $2.2M | $1.6M | $1.7M | $732.0K |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-121.3M | $45.9M | — | — | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $23.8M | $996.0K | — | — | — |
| Net Change in Cash | $72.9M | $44.8M | $-4.6M | $55.7M | $-6.0M |
| Free Cash Flow | $168.8M | $-4.2M | $-29.0M | $30.1M | $-8.7M |